(4-(4-fluorobenzyl)piperazin-1-yl)(1H-indol-2-yl)methanone | 1146213-76-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (4-(4-fluorobenzyl)piperazin-1-yl)(1H-indol-2-yl)methanone
• 英文别名: [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-(1H-indol-2-yl)methanone
• CAS: 1146213-76-4
• 化学式: C₂₀H₂₀FN₃O
• 分子量: 337.397
• InChiKey: XLXHFVHCXZQGOS-UHFFFAOYSA-N

物化性质

• 熔点：
  170.9 °C
• 沸点：
  533.4±50.0 °C(predicted)
• 密度：
  1.294±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-(4-fluorobenzyl)piperazin-1-yl)(1H-indol-2-yl)methanone 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 丙酮 为溶剂， 反应 1.0h， 以97%的产率得到(3-bromo-1H-indol-2-yl)(4-(4-fluorobenzyl)piperazin-1-yl)methanone
  参考文献：
  名称：

  Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase

  摘要：

  The p38 MAP kinase is implicated in the release of the pro-inflammatory cytokines TNF alpha and IL-1b. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A new lead structure for p38 MAP kinase inhibition was identified. Herein, we report the SAR of this new class of p38 inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.023
• 作为产物：
  描述：

  吲哚-2-羧酸 、 1-(4-氟苄基)哌嗪 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 以61%的产率得到(4-(4-fluorobenzyl)piperazin-1-yl)(1H-indol-2-yl)methanone
  参考文献：
  名称：

  Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase

  摘要：

  The p38 MAP kinase is implicated in the release of the pro-inflammatory cytokines TNF alpha and IL-1b. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A new lead structure for p38 MAP kinase inhibition was identified. Herein, we report the SAR of this new class of p38 inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.023

文献信息

• Novel benzofurans and indols
  申请人：Wellner Eric

  公开号：US20050192288A1

  公开（公告）日：2005-09-01

  Compounds of formula (I) wherein X is a fluorine or a chlorine atom; the methyl groups located at the 2- and 5-position of the piperazine ring are in trans-configuration to each other; Y is NH or O; R 1 is selected front hydrogen, chloro, bromo, nitro, methyl or trifluoromethyl; R 2 is selected from hydrogen, halo, methyl, trifluoromethyl, methoxy or trifluoromethoxy; or a pharmaceutically acceptable salt or solvate thereof, The invention also relates to pharmaceutical compositions containing a compound of formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of compounds of formula (I), as well as methods for treating mammals suffering from inflammatory, autoimmune, proliferative or hyperproliferative diseases by administering a compound having the formula (I) to said mammal.

  式(I)的化合物，其中X是氟或氯原子；位于哌嗪环的2-和5-位置的甲基基团相对于彼此处于反式构型；Y是NH或O；R1从氢、氯、溴、硝基、甲基或三氟甲基中选择；R2从氢、卤、甲基、三氟甲基、甲氧基或三氟甲氧基中选择；或其药学上可接受的盐或溶剂，本发明还涉及含有式(I)的化合物的药物组合物，连同药学上可接受的载体。还包括制备式(I)化合物的方法，以及通过向哺乳动物投与具有式(I)的化合物来治疗患有炎症、自身免疫、增殖或过度增殖疾病的哺乳动物的方法。
• Novel Benzofurans and Indols
  申请人：WELLNER Eric

  公开号：US20080119485A1

  公开（公告）日：2008-05-22

  Compounds of formula (I) wherein X is a fluorine or a chlorine atom; the methyl groups located at the 2- and 5-position of the piperazine ring are in trans-configuration to each other; Y is NH or O; R 1 is selected from hydrogen, chloro, bromo, nitro, methyl or trifluoromethyl; R 2 is selected from hydrogen, halo, methyl, trifluoromethyl, methoxy or trifluoromethoxy; or a pharmaceutically acceptable salt or solvate thereof; The invention also relates to pharmaceutical compositions containing a compound of formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of compounds of formula (I), as well as methods for treating mammals suffering from inflammatory, autoimmune, proliferative or hyperproliferative diseases by administering a compound having the formula (I) to said mammal.

  化合物的公式(I)，其中X是氟或氯原子；位于哌嗪环的2-和5-位的甲基基团相对构型为反式；Y是NH或O；R1从氢、氯、溴、硝基、甲基或三氟甲基中选择；R2从氢、卤、甲基、三氟甲基、甲氧基或三氟甲氧基中选择；或其药学上可接受的盐或溶剂；发明还涉及含有公式(I)化合物的药物组合物和制备公式(I)化合物的方法，以及通过向哺乳动物投与具有公式(I)的化合物来治疗患有炎症、自身免疫、增殖或过度增殖疾病的哺乳动物的方法。
• NOVEL BENZOFURANS AND INDOLS
  申请人：Active Biotech AB

  公开号：EP1718612A1

  公开（公告）日：2006-11-08
• US7339059B2
  申请人：——

  公开号：US7339059B2

  公开（公告）日：2008-03-04
• [EN] NOVEL BENZOFURANS AND INDOLS<br/>[FR] NOUVEAUX BENZOFURANES ET INDOLES
  申请人：ACTIVE BIOTECH AB

  公开号：WO2005080336A1

  公开（公告）日：2005-09-01

  Compounds of formula (I) wherein X is a fluorine or a chlorine atom; the methyl groups located at the 2- and 5-position of the piperazine ring are in trans­configuration to each other; Y is NH or O; Rl is selected from hydrogen, chloro, bromo, nitro, methyl or trifluoromethyl; R2 is selected from hydrogen, halo, methyl, trifluoromethyl, methoxy or trifluoromethoxy; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions containing them and their use in therapy for treating inflammatory, autoimmune, proliferative or hyperproliferative diseases.